@ARTICLE{
author={Brodowicz Thomas,Ciuleanu Tudor E,Radosavljevic Davorin Z,Shacham-Shmueli Einat,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank M,Purkalne Gunta,Messinger D,Zielinski Christoph},
year={2013},
title={FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study},
journal={ANNALS OF ONCOLOGY},
volume={24},
number={7},
pages={1769-1777},
document_type={Article},
} 

@ARTICLE{
author={Jassem Jacek,Pienkowski Tadeusz,Pluzanska Anna,Jelic Svetislav B,Gorbunova Vera,Mrsic-Krmpotic Zrinka,Berzins Juris,Nagykalnai Thomas,Wigler N,Renard J,Munier Stephane,Weil C},
year={2001},
title={Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={19},
number={6},
pages={1707-1715},
document_type={Article},
}